Prof. Dr. Lafosse and RevArte Featured in Belgian Media for Integrating neuroClues® in Neurorehabilitation
At RevArte in Edegem, clinicians are exploring how eye movements can reveal neurological disorders years before symptoms …
JOIN THE ADVENTURE: Become a neuroClues Shareholder
Brussels, 27 January 2026 — Today, we at P3lab (doing business as neuroClues) are launching our crowdfunding campaign on …
Concussion Assessment and Monitoring with Eye Movement Biomarkers
Clinical highlights – November 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, av …
Instability of Neurological Diagnosis
Clinical highlights – June 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, availa …
Reliability of Oculomotor Biomarkers
Clinical highlights – May 2025 neuroClues® has officially received its CE-marking as a Class IIa medical device, availab …
Exploring Anti-Saccades and Frontal Lobe Function
Clinical highlights – April 2025 neuroClues has officially received its CE-marking as a Class IIa medical device, availa …
Neural Pathways of Voluntary and Reflexive Saccades
Clinical highlights – March 2025 In this article, we explore the differences between voluntary and reflexive saccades, t …
Oculomotor Biomarkers Recorded on 50 Patients with neuroClues®, now CE-Marked!
Clinical highlights – February 2025 This month’s newsletter is eye-opening. As you may know, neuroClues® has officially …
.png)
neuroClues secures CE certification for its eye-tracking technology set to enhance neurologic care
In summary neuroClues achieves Medical Device Regulation (MDR) certification and is now allowed to issue the CE-mark on …
